Application of rhenium-188 HEDP in bone metastases therapy.
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less radiotoxic and more effective radiopharmaceuticals is therefore a challenge for radiopharmacists and industry. This paper reviews the application of rhenium-188 HEDP as a reactor- or generator-produced nuclide for bone metastases therapy.
Department of Nuclear Medicine, Medical University, Gdańsk, Poland. jscheffler@wp.pl
Justyna
J
Scheffler
Mirosława
M
Derejko
Tomasz
T
Bandurski
Grzegorz
G
Romanowicz
D001859:Bone Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D012968:Etidronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D009942:Organometallic Compounds; D010146:Pain / Q000209:etiology / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D010818:Practice Patterns, Physicians'; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012211:Rhenium / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome
D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid